← Back to Search

Diagnostic Test

68Ga -DOTATATE PET scans for Neuroendocrine Tumors

N/A

Waitlist Available

Led By Ur Metser, M.D.

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up na. one time visit for 68ga-dotatate pet scan

Awards & highlights

Study Summary

This trial is testing whether PET scans using 68Ga-DOTATATE can help manage neuroendocrine tumours by seeing if the scans change how patients are treated.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ na. one time visit for 68ga-dotatate pet scan

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~na. one time visit for 68ga-dotatate pet scan

This trial's timeline: 3 weeks for screening, Varies for treatment, and na. one time visit for 68ga-dotatate pet scan for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Detection of additional disease and/or change in extent of disease after 68Ga-DOTATATE PET

Secondary outcome measures

To determine the proportion of patients with NET (or clinical suspicion of NET) in whom intended clinical management prior to PET is changed after 68Ga-DOTATATE PET.

Trial Design

1Treatment groups

Experimental Treatment

Group I: 68Ga -DOTATATE PET scanExperimental Treatment1 Intervention

Single arm study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

68Ga -DOTATATE PET scans

2019

N/A

~1920

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,468 Previous Clinical Trials

482,574 Total Patients Enrolled

5 Trials studying Neuroendocrine Tumors

770 Patients Enrolled for Neuroendocrine Tumors

Ur Metser, M.D.Principal InvestigatorPrincess Margaret Cancer Centre

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the enrollment capacity of this scientific experiment?

"Affirmative. Records on clinicaltrials.gov state that this medical study, initially posted on March 28th 2019, is still recruiting patients. From one location, 2000 individuals are needed to participate in the trial."

Answered by AI

Are there any open spots in this research endeavor?

"According to the clinicaltrials.gov listing, this medical trial is still actively recruiting participants since its initial post on March 28th 2019 and most recent update on November 25th 2021."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

68Ga-DOTATATE PET for Management of Neuroendocrine Tumors

2019. "68Ga-DOTATATE PET for Management of Neuroendocrine Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03873870.